BB&T Securities LLC acquired a new position in TESARO, Inc. (NASDAQ:TSRO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,593 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.
Several other institutional investors have also added to or reduced their stakes in the company. KBC Group NV acquired a new stake in shares of TESARO in the second quarter worth $707,000. BNP Paribas Arbitrage SA increased its position in shares of TESARO by 317.8% in the second quarter. BNP Paribas Arbitrage SA now owns 3,326 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 2,530 shares in the last quarter. Legal & General Group Plc increased its position in shares of TESARO by 254.5% in the second quarter. Legal & General Group Plc now owns 37,218 shares of the biopharmaceutical company’s stock worth $5,206,000 after acquiring an additional 26,719 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of TESARO by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 703,774 shares of the biopharmaceutical company’s stock worth $98,430,000 after acquiring an additional 28,177 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of TESARO in the second quarter worth $351,000.
TSRO has been the subject of several recent research reports. ValuEngine raised shares of TESARO from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $199.00 price objective on shares of TESARO and gave the stock a “buy” rating in a research report on Sunday, June 4th. Cann reissued a “buy” rating and issued a $199.00 price objective on shares of TESARO in a research report on Monday, June 5th. FBR & Co dropped their price objective on shares of TESARO from $200.00 to $195.00 and set a “mkt perform” rating for the company in a research report on Monday, June 5th. Finally, Wedbush raised shares of TESARO to an “outperform” rating and set a $168.00 price target for the company in a report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. TESARO has an average rating of “Buy” and a consensus target price of $171.42.
In other TESARO news, VP Edward C. English sold 10,862 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the sale, the vice president now owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Grant C. Bogle sold 14,167 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The disclosure for this sale can be found here. Insiders sold a total of 35,100 shares of company stock worth $4,558,765 in the last three months. Insiders own 40.50% of the company’s stock.
TESARO, Inc. (NASDAQ:TSRO) opened at 119.04 on Friday. TESARO, Inc. has a 1-year low of $96.52 and a 1-year high of $192.94. The firm’s 50-day moving average is $121.03 and its 200-day moving average is $138.94. The company’s market capitalization is $6.45 billion.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by ($0.30). The business had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The company’s quarterly revenue was down 17.6% compared to the same quarter last year. During the same period last year, the firm earned ($1.28) EPS. Equities research analysts predict that TESARO, Inc. will post ($8.61) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://baseballnewssource.com/markets/bbt-securities-llc-acquires-new-stake-in-tesaro-inc-tsro/1601310.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with our FREE daily email newsletter.